Table 3 Genotype profile of the different genes related with resistance to SP, AQ or the combination of both
No of mutations | Combination | Haplotype | Yambio (N = 532) | |
|---|---|---|---|---|
N (%) | 95% CI | |||
Genotype of genes related with resistance to SP | ||||
Pfdhfr | ||||
3 | 51I/59R/108N | IRN | 446 (83.8%) | 85–87 |
3 | 51I/108N/164L | INL | 1 (0.2%) | 0.0–1 |
4 | 51I/59R/108N/164L | IRNL | 2 (0.4%) | 0.1–1 |
Pfdhfr + Pfdhps | ||||
4 | 51I/59R/108N/437G* | IRNG | 367 (68.9%) | 65–73 |
5 | 51I/59R/108N/437G/540E** | IRNGE | 332 (62.4%) | 58–66 |
6 | 51I/59R/108N/437G/540E/581G*** | IRNGEG | 24 (4.5%) | 3–7 |
Genotype genes related with resistance to AQ and different anti-malarial drugs | ||||
Pfmdr1 | ||||
1 | 86Y | Y | 101 (18.9%) | 16–22 |
1 | 1246Y | Y | 51 (9.5%) | 7–1 |
2 | 86Y/ 1246Y | YY | 23 (4.3%) | 3–6 |
Pfcrt | ||||
1 | 76 T | T | 113 (21.2%) | 18–25 |
Pfmdr1 + Pfcrt | ||||
3 | 86Y/1246Y/76 T | YYT | 16 (3%) | 17–48 |
Combination of mutations related with SP and AQ resistance | ||||
Pfdhfr + pfdhps + pfmdr1 | ||||
6 | 51I/59R/108N/437G/540E/86Y/ | IRNGEY | 8 (1.5%) | |
7 | 51I/59R/108N/437G/540E/86Y/1246Y | IRNGEYY | 7 (1.3%) | |
7 | 51I/59R/108N/437G/540E/581G/86Y | IRNGEGY | 1 (0.18%) | |
Pfdhfr + pfdhps + pfmdr1 + pfcrt | ||||
8 | 51I/59R/108N/437G/540E/86Y/1246Y/76 T | IRNGEYYT | 6 (1.12%) | |